FOS and neoplasm: Interestingly, significantly higher levels of Fos – the previously identified downstream target of MAPK signaling – were found in DDKC cells, suggesting its potential role as a crucial driver of DKK3‐loss effects throughout tumor progression even in the absence of upstream MAPK signaling (Figure 3L).